Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(<i>N</i>,<i>N</i>-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance

<div>Insulin receptor and GLUT-4 in the liver and visceral white adipose tissue after V10-DMAP treatments. Photomicrographs show immunoreactivity to the insulin receptor and GLUT-4, both marked in green and counterstain with DAPI for nuclei, in the liver and adipose tissue. (a)–(d) Hepatic biopsies, insulin receptor phosphorylated in tyrosine (Tyr 1162/1163), and magnification 20x. (e)–(h) Visceral white adipose biopsies, insulin receptor phosphorylated in tyrosine (Tyr 1162/1163), and magnification 40x. (i)–(l) Visceral white adipose biopsies, glucose transporter type 4 insulin-dependent, and magnification 40x.</div>

Bioinorganic Chemistry and Applications

fig5

Figure 5

Figure 5: Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(<i>N</i>,<i>N</i>-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance 

Figure 5 | Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(N,N-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance 